-
-
-
-
-
-
-
Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
-
-
-
-
-
-
-
Regeneron (REGN) Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio (TSVT) Platforms and Preclinical and Clinical Programs
-
-
-
-
-
-
-
Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs
-
-
-
-
-
-
-
Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
-
-
-
-
-
-
-
Regeneron (REGN) Completes Checkmate Pharmaceuticals Acquisition
-
-
-
-
-
-
-
Regeneron (REGN) Acquires Checkmate Pharmaceuticals (CMPI) for $10.50/sh Cash
-
-
-
-
-
-
-
Regeneron (REGN) Announces FDA Approves First-in-class Evkeeza for Patients with Ultra-rare Inherited Form of High Cholesterol
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

